Company intelligence / Profile preview

Taivex Therapeutics

Taipei City, Taipei, Taiwantaivex.com ↗

Ownership: Private
Development stage: Other

Overview

T‑1101 completed Phase I with encouraging safety and preliminary efficacy in neuroendocrine tumors; recommended Phase II dose established. T‑1201 nearing end of Phase I with promising safety/efficacy in melanoma/cholangiocarcinoma. T‑1301 is in ongoing Phase I for GIST/AML. T‑1501 is preclinical, expected to enter clinic in late 2025.

Therapeutic areas: Oncology
Modalities: Small moleculesSmall molecule-drug conjugatesMulti-target tyrosine kinase inhibitors
Industry: Biotech

Drug pipeline

4 assets

T-1301

3 more assets in the full pipeline.

Request access →

Partnerships

National Health Research Institutes Taiwan—technology transfer and co-development on multiple assetsDevelopment Center for Biotechnology—co-development on early programs

Beyond the preview

Go deeper on Taivex Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taivex Therapeutics.

Explore the full profile